During this fireside chat, we welcome Reviva Pharmaceuticals, ticker, RVPH on the NASDAQ, and their CEO, Dr. Lax Bhat. Reviva is a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases. The Company’s lead drug candidate, brilaroxazine, is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms.

This Fireside Chat was recorded during the Lytham Partners Spring 2023 Investor Conference.